CME Presentations

Mantle Cell Lymphoma



  • Matthew Matasar, MD

    Matthew Matasar, MD

    Matthew Matasar, MD

    Chief, Division of Blood Disorders

    Mattew Matasar, MD, MPH, joined Memorial Sloan Kettering Cancer Center to pursue advanced training in cancer medicine and has been dedicated to caring for patients with lymphoma ever since. His research is focused on finding new and better ways to treat lymphoma, particularly high-risk aggressive lymphomas, and certain uncommon types of non-Hodgkin lymphoma. Last year, Dr. Matasar joined the Rutgers Cancer Institute of New Jersey and RWJBarnabas Health. He joins a team of professionals here that are deeply committed to the art and science of caring for people facing a diagnosis of cancer. Dr. Matasar is committed to ensuring his patients receive the best treatments delivered in the best ways, and to being a partner and advocate to guide them through what can be a very difficult time.

CME Information

Global Logo PQH Logo

A Growing Momentum in Untreated Mantle Cell Lymphoma

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD).


This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.


Monday, December 18, 2023 from 11:30am-12:00pm ET


The target audience for this activity are hematologic oncologists, hematologists, medical oncologists, internists, primary care physicians, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the diagnosis and management of patients with MCL.


With many changes to the treatment landscape for mantle cell lymphoma (MCL) anticipated over the next two years, clinicians need to stay up to date with the latest advances and prepare to address practical issues, such as identifying the most appropriate therapy for each patient and managing treatment‐associated adverse events.

Join Dr. Matthew Matasar, an expert hematologic oncologist to discuss the importance of determining mutational profiles and making a differential diagnosis of MCL so treatment can be initiated promptly. Dr. Matasar will also review the limitations of chemoimmunotherapy, the rationale for better upfront treatment options, and emerging targeted treatment strategies.


After completing this activity, the participant should be better able to:
  • Review clinical presentations, gene mutations, and differential diagnoses of MCL
  • Discuss the unmet need for treatment in earlier settings for MCL and the potential of targeted Approaches



In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 30 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Conflicts of Interest
Matthew Matasar, MD
Chief, Division of Blood Disorders
Rutgers CINJ and RWJBarnabas Health
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
Honoraria and stipends: ADC Therapeutics; AstraZeneca; BMS; Celgene; Epizyme; IMV Therapeutics; Kite; Regeneron; Seagen
Consultant, Advisor, Speaker: Bayer; Genentech; Juno Therapeutics; Merck; Roche; Seattle Genetics; Takeda; Teva
Researcher: Bayer; Genentech; GM Biosciences; Immunovaccine Technologies; Janssen; Pharmacyclics; Roche; Seattle Genetics
Honoraria: Bayer; Immunovaccine Technologies; Janssen; Pharmacyclics; Roche; Seattle Genetics; Takeda
Individual publicly traded stocks and stock options: Equity ownership - Merck

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For additional information about the accreditation of this activity, please visit

Technical Support:

For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at